If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitiligo, addressing important treatment needs ...
Positive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of Severity of Alopecia Tool (SALT) score = 20 and key ...
A 93-year-old woman presented with sequential bilateral decreased vision within 2 weeks.Symptoms initially began in the right ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results